Antimicrobial therapy for shigellosis

Reviews of Infectious Diseases

Volumn 13, Issue , 1991, Pages S332-S341

  Salam, Mohammed A ^a   Bennish, Michael L ^a  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; ENOXACIN; FURAZOLIDONE; KANAMYCIN; NALIDIXIC ACID; NEOMYCIN; NORFLOXACIN; PIVMECILLINAM; QUINOLONE DERIVATIVE; STREPTOMYCIN; SULFADIAZINE; SULFADIMIDINE; SULFAGUANIDINE; SULFAMETHOXAZOLE; SULFONAMIDE; TRIMETHOPRIM;

CONFERENCE PAPER; DRUG COST; DRUG DOSE; DRUG EFFICACY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHIGELLA DYSENTERIAE; SHIGELLOSIS;

ANTI-INFECTIVE AGENTS; COMBINED MODALITY THERAPY; DEVELOPING COUNTRIES; DYSENTERY, BACILLARY; FLUID THERAPY; HUMAN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.;

EID: 0026064508     PISSN: 01620886     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/13.Supplement_4.S332     Document Type: Article

References (109)

1. Anderson DEW, Cruickshank R, Walker J. The treatment of bacillary (Flexner) dysentery with sulphanilylguanidine. BMJ 1941;2:497-501
2. Cooper ML, Zucker RL, Wagoner S. Sulfa thiazole for acute diarrhea and dysentery of infants and children. JAMA 1941;117:1520-3
3. Marshall EK, Bratton AC, Edwards LB, Walker E. Sulfanilylguani-dine in the treatment of acute bacillary dysentery in children. Bulletin of the Johns Hopkins Hospital 1941;68:94-111
4. Reitler R, Marberg K. Note on the treatment of acute bacillary dysentery with sulphapyridine. BMJ 1941;1:277-8
5. Fairley NH, Boyd JSK. Treatment of bacillary dysentery with sul-phaguanidine. Lancet 1942;1:20-1
6. Hardy AV, Watt J, Peterson J, Schlosser E. Studies of the acute diarrheal diseases. VIII. Sulfaguanidine in the control of Shigella dysen- teriae infections. Public Health Rep 1942;57:529-35
7. Hardy AV, Bums W, Decapito T. Studies of the acute diarrheal diseases. X A. Cultural observations on the relative efficacy of sulfonamides in Shigella dysenteriae infections. Public Health Rep 1943;58:689-93
8. Hardy AV, Cummins SD. Studies of the acute diarrheal diseases. X B. A preliminary note on the clinical response to sulfadiazine therapy. Public Health Rep 1943;58:693-6
9. The burden of disease resulting from diarrhea. In: Katz SL, ed. New vaccine development: establishing priorities. Vol. 2. Diseases of importance in developing countries. Washington, DC: National Academy Press, 1986:165
10. Bennish ML, Harris JR, Wojtyniak BJ, Struelens M. Death in shigel-losis: incidence and risk factors in hospitalized patients. J Infect Dis 1990;161:500-6
11. Stoker DJ. Treatment of bacillary dysentery: with special reference to stosstherapy with tetracycline. BMJ 1962;1:1179-81
12. Haltalin KC, Nelson JD, Ring R 3rd, Sladoje M, Hinton LV. Double blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo. J Pediatr 1967;70:970-81
13. Haltalin KC, Nelson JD, Hinton LV, Kusmiesz HT, Sladoje M. Comparison of orally absorbable and nonabsorbable antibiotics in shigellosis. A double-blind study with ampicillin and neomycin. J Pediatr 1968;72:708-20
14. Tong MJ, Martin DG, Cunningham JJ, Gunning J-J. Clinical and bacteriological evaluation of antibiotic treatment in shigellosis. JAMA 1970;214:1841-4
15. Lexomboon U, Mansuwan P, Duangmani C, Benjadol P, McMinn MT. Clinical evaluation of co-trimoxazole and furazolidone in treatment of shigellosis in children. BMJ 1972;1:23-6
16. Haltalin KC, Kusmiesz HT, Hinton LV, Nelson JD. Treatment of acute diarrhea in outpatients. Double-blind study comparing ampicillin and placebo. Am J Dis Child 1972;124:554-61
17. Kabir I, Butler T, Khanam A. Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo- controlled trial. Antimicrob Agents Chemother 1986;29:645-8
18. Salam MA, Bennish ML. Therapy for shigellosis. 1. Randomized, double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 1988;113:901-7
19. Stoll BJ, Glass RI, Huq MI, Khan MU, Banu H, Holt J. Epidemiologic and clinical features of patientsinfected with Shigella who attended a diarrheal disease hospital in Bangladesh. J Infect Dis 1982; 146:177-83
20. Keusch GT, Formal SB, Bennish ML. Shigellosis. In: Warren KS, Mahmoud AAF, eds. Tropical and geographical medicine. 2nd ed. New York: McGraw-Hill Information Services Co., 1990:762-76
21. Butler T, Islam MR, Azad MAK, Jones PK. Risk factors for development of hemolytic uremic syndrome during shigellosis. J Pediatr 1987;110:894-7
22. Gangarosa EJ, Perera DR, Mata U, Mendizábal-Morris C, Guzman G, Reller LB. Epidemic Shiga bacillus dysentery in Central America. II. Epidemiologic studies in 1969. J Infect Dis 1970;122:181-90
23. Rahaman MM, Khan MM, Aziz KMS, Islam MS, Kibriya AKMG. An outbreak of dysentery caused by Shigella dysenteriae type 1 on a coral island in the Bay of Bengal. J Infect Dis 1975;132:15-9
24. Pickering LK, DuPont HL, Olarte J. Single-dose tetracycline therapy for shigellosis in adults. JAMA 1978;239:853-4
25. Nelson JD, Haltalin KC. In-vitro susceptibility of E. coli, Shigellae and Salmonellae to kanamycin and therapeutic implications. Ann N Y Acad Sci 1966;132:1006-12
26. Haltalin KC, Nelson JD. Failure of furazolidone therapy in shigellosis. Am J Dis Child 1972;123:40-4
27. Nunnery AW, Riley HD Jr. Gentamicin: clinical and laboratory studies in infants and children. J Infect Dis 1969;119:460-4
28. Haltalin KC, Nelson JD, Kusmiesz HT, Hinton LV. Comparison of intramuscular and oral ampicillin therapy for shigellosis. J Pediatr 1968;73:617-22
29. Orenstein WA, Ross L, Overturf GD, Wilkins J, Redfield DR, Underman A. Antibiotic treatment of acute shigellosis: failure of cefaman- dole compared with trimethoprim/sulfamethoxazole and ampicillin. Am J Med Sci 1981;282:27-33
30. Nelson JD, Kusmiesz H, Shelton S. Oral or intravenous trimethoprim-sulfamethoxazole therapy for shigellosis. Rev Infect Dis 1982; 4:546-50
31. Nelson JD, Haltalin KC. Amoxicillin less effective than ampicillin against Shigella in vitro and in vivo: relationship of efficacy to activity in serum. J Infect Dis 1974;129(Suppl):S222-7
32. Haltalin KC, Nelson JD, Kusmiesz HT, Hinton LV. Optimal dosage of ampicillin for shigellosis. J Pediatr 1969;74:627-31
33. Gilman RH, Koster F, Islam S, McLaughlin J, Rahaman MM. Randomized trial of high- and low-dose ampicillin therapy for treatment of severe dysentery due to Shigella dysenteriae type 1. Antimicrob Agents Chemother 1980;17:402-5
34. Lionel NDW, Abeyasekera FJB, Samarasinghe HG, Goonewardena CV, Tawil GS. A comparison of a single dose and a five-day course of tetracycline therapy in bacillary dysentery. J Trop Med Hyg 1969; 72:170-2
35. Gilman RH, Spira W, Rabbani H, Ahmed W, Islam A, Rahaman MM. Single-dose ampicillin therapy for severe shigellosis in Bangladesh. J Infect Dis 1981;143:164-9
36. Gotuzzo E, Oberhelman RA, Maguiiña C, Berry SJ, Yi A, Guzman M, Ruiz R, Leon-Barua R, Sack RB. Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults. Antimicrob Agents Chemother 1989;33:1101-4
37. Watanabe T. Infective heredity of multiple drug resistance in bacteria. Bacteriological Reviews 1963;27:87-115
38. Marbeig K, Altmann G, Eshkol-Bruck A. Observations on resistance to sulfadiazine and antibiotics in shigellosis. Am J Trop Med Hyg 1958;7:51-7
39. Ross S, Controni G, Khan W. Resistance of shigellae to ampicillin and other antibiotics. Its clinical and epidemiological implications. JAMA 1972;221:45-7
40. Weissman JB, Gangarosa EJ, DuPont HL. Changing needs in the antimicrobial therapy of shigellosis. J Infect Dis 1973;127:611-3
41. Shahid NS, Rahaman MM, Haider K, Banu H, Rahman N. Changing pattern of resistant Shiga bacillus (Shigella dysenteriae type 1) and Shigella flexneri in Bangladesh. J Infect Dis 1985;152:1114-9
42. Levy SB, FitzGerald GB, Macone AB. Changes in intestinal flora of farm personnel after introduction of a tetracycline-supplemented feed on a form. N Engl J Med 1976;295:583-8
43. Committee on human health risk assessment of using subtherapeutic antibiotics in animal feed. Human health risks with the subtherapeutic use of penicillin or tetracyclines in animal feed. Washington, DC: National Academy Press, 1989
44. Hossain MM, Glass RI, Khan MR. Antibiotic use in a rural community in Bangladesh. Int J Epidemiol 1982;11:402-5
45. Ronsmans C, Bennish ML, Chakraborty J, Fauveau V. Current practices for treatment of dysentery in rural Bangladesh. Rev Infect Dis 1991;13(Suppl 4):S351-6
46. Bennish M. The Bangladesh drug policy: the next step-using good drugs “goodly.” Bangladesh Journal of Child Health 1987;11:63-72
47. The management of diarrhoea and use of oral rehydration therapy: a joint WHO/UNICEF statement. 2nd ed. Geneva: World Health Organization, 1985
48. A manual for the treatment of acute diarrhoea for use by physicians and other senior health workers. World Health Organization publication no. WHO/CDD/SER/80.2 Rev.l Geneva: World Health Organization, 1984
49. Grant J. State of the world’s children 1989. Oxford: Oxford University Press, 1989:94-5
50. Nelson JD, Kusmiesz H, Jackson LH, Woodman E. Trimethoprim-sulfemethoxazole therapy for shigellosis. JAMA 1976;235:1239-43
51. Chang MJ, Dunkle LM, Van Reken D, Anderson D, Wong ML, Feigin RD. Trimethoprim-sulfamethoxazole compared to ampicillin in the treatment of shigellosis. Pediatrics 1977;59:726-9
52. Yunus M, Rahman ASMM, Farooque ASG, Glass RI. Clinical trial of ampicillin v. trimethoprim sulphamethoxazole in the treatment of Shigella dysentery. J Trop Med Hyg 1982;85:195-9
53. Bogaerts J, Habyalimana JB, Chevolet T, Vandepitte J. Treatment of severe bacillary dysentery with trimethoprim alone. Trans R Soc Trop Med Hyg 1985;79:203-5
54. Pal SC. Epidemic bacillary dysentery in West Bengal, India, 1984 [letter]. Lancet 1984;1:1462
55. Bennish M, Eusof A, Kay B, Wierzba T. Multiresistant Shigella infections in Bangladesh [letter]. Lancet 1985;2:441
56. Frost JA, Willshaw GA, Barclay EA, Rowe B. Plasmid characterization of drug-resistant Shigella dysenteriae l from an epidemic in Central Africa. Journal of Hygiene (Cambridge) 1985;94:163-72
57. Centers for Disease Control. Multiply resistant shigellosis in a day care center—Texas. MMWR 1986;35:753-5
58. Centers for Disease Control. Nationwide dissemination of multiply resistant Shigella sonnei following a common-source outbreak. MMWR 1987;36:633-4
59. Frost JA, Rowe B, Vandepitte J. Acquisition of trimethoprim resistance in epidemic strain of Shigella dysenteriae type 1 from Zaire [letter], Lancet 1982;1:963.
60. Parry HE. Nalidixic acid for shigellosis [letter]. Lancet 1983;2:1206
61. Malengreau M. Nalidixic acid in Shigella dysenteriae outbreaks [letter]. Lancet 1984;2:172
62. Bose R, Nashipuri JN, Sen PK, Datta P, Bhattacharya SK, Datta D, Sen D, Bhattacharya MK. Epidemic of dysentery in West Bengal: clinicians' enigma [letter]. Lancet 1984;2:1160.
63. Moorhead PJ, Parry HE. Treatment of Sonne dysentery. BMJ 1965; 2:913-5
64. Haltalin KC, Nelson JD, Kusmiesz HT. Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis. Arch Dis Child 1973;48:305-12
65. Hansson HB, Barkenius G, Cronberg S, Juhlin I. Controlled comparison of nalidixic acid or lactulose with placebo in shigellosis. Scand J Infect Dis 1981;13:191-3
66. Ingham B, Brentnall DW, Dale EA, McFadzean JA. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. Toxicol Lett 1977;1:21-6
67. Schaad UB, Wedgwood-Krucko J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 1987; 15:165-8
68. Buchbinder M, Webb JC, Anderson LV, McCabe WR. Laboratory studies and clinical pharmacology of nalidixic acid (WIN 18, 320). Antimicrob Agents Chemother 1962;308-17
69. Ronald AR, Turck M, Petersdorf RG. A critical evaluation of nalidixicacid in urinaiy-tract infections. N Engl J Med 1966;275:1081-9
70. Panhotra BR, Desai B, Sharma PL. Nalidixic-acid-resistant Shigella dysenteriae 1 [letter]. Lancet 1985;1:763
71. Munshi MH, Sack DA, Haider K, Ahmed ZU, Rahaman MM, Morshed MG. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet 1987;2:419-21
72. Chin N-X, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1984;25:319-26
73. Sanders CC, Sanders WE Jr., Goering RV, Werner V. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother 1984;26:797-801
74. Keusch GT, Bennish ML. Shigella. In: Farthing MJG, Keusch GT, eds. Enteric infection. Mechanisms, manifestations, and management. New York: Raven Press, 1988:278
75. Ling J, Kam KM, Lam AW, French GL. Susceptibilities of Hong Kong isolates of multiply resistant Shigella spp. to 25 antimicrobial agents, including ampicillin plus sulbactam and new 4-quinolones. Antimicrob Agents Chemother 1988;32:20-3
76. Carlson JR, Thornton SA, DuPont HL, West AH, Mathewson JJ. Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens. Antimicrob Agents Chemother 1983;24: 509-13
77. Goossens H, De Mol P, Coignau H, Levy J, Grados O, Ghysels G, Innocent H, Butzler J-P. Comparative in vitro activities of aztreo- nam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrob Agents Chemother 1985;27:388-92
78. Wolfson JS, Hooper DC. Norfloxacin: a new targeted fluoroquinolone antimicrobial agent. Ann Intern Med 1988;108:238-51
79. Hoffken G, Lode H, Prinzing C, Borner K. Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 1985;27:375-9
80. Davis RL, Koup JR, Williams-Warren J, Weber A, Smith AL. Pharmacokinetics of three oral formulations of ciprofloxacin. Antimicrob Agents Chemother 1985;28:74-7
81. Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis. II. Randomized double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990;162:711-6
82. Rogerie F, Ott D, Vandepitte J, Verbist L, Lemmens P, Habiyaremye I. Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type l in adults. Antimicrob Agents Chemother 1986;29:883-6
83. De Mol P, Mets T, Lagasse R, Vandepitte J, Mutwewingabo A, Butzler J-P. Treatment of bacillary dysentery: a comparison between enoxacin and nalidixic acid. J Antimicrob Chemother 1987;19:695-8
84. Lolekha S, Patanachareon S, Thanangkul B, Vibulbandhitkit S. Norflox acin versus co-trimoxazole in the treatment of acute bacterial diarrhoea: a placebo controlled study. Scand J Infect Dis Suppl 1988; 56:35-45
85. Wade VA, Mansfield PR, McDonald PJ. Drug companies’ evidence to justify advertising. Lancet 1989;2:1261-4.
86. Ciprofloxacin. Med Lett Drugs Ther 1988;30:11-3
87. Spratt BG. Comparison of the binding properties of two 6-/3-amidinopenicillanic acid derivatives that differ in their physiological effects on Escherichia coli. Antimicrob Agents Chemother 1977;11:161-6
88. Spratt BG. The mechanism of action of mecillinam. J Antimicrob Chemother 1977;3(Suppl B):13-9
89. Kucers A, Bennett NM. The use of antibiotics. A comprehensive review with clinical emphasis. 4th ed. Philadelphia: J. B. Lippincott, 1987:256
90. Tybring L, Melchior NH. Mecillinam (FL 1060), a 6-β-amidino-penicillanic acid derivative: bactericidal action and synergy in vitro. Antimicrob Agents Chemother 1975;8:271-6
91. Richmond MH. In vitro studies with mecillinam on Escherichia coliand Pseudomonas aeruginosa. J Antimicrob Chemother 1977;3(Suppl B): 29-39
92. Uwaydah M, Osseiran M. Susceptibility of recent Shigella isolates to mecillinam, ampicillin, tetracycline, chloramphenicol, and cotrimox- azole. J Antimicrob Chemother 1981;7:619-22
93. Hansson HB, Walder M, Juhlin I. Susceptibility of shigellae to mecillinam, nalidixic acid, trimethoprim, and five other antimicrobial agents. Antimicrob Agents Chemother 1981;19:271-3
94. Neu HC. Mecillinam, a novel penicillanic acid derivative with unusual activity against gram-negative bacteria. Antimicrob Agents Chemother 1976;9:793-9
95. Greenwood D. Effect of osmolality on the response of Escherichia colito mecillinam. Antimicrob Agents Chemother 1976;10:824-6
96. Kabir I, Rahaman MM, Ahmed SM, Akhter SQ, Butler T. Comparative efficacies of pivmecillinam and ampicillin in acute shigellosis. Antimicrob Agents Chemother 1984;25:643-5
97. Rabbani GH, Gilman RH, Spira WM. Intestinal fluid loss in Shigella dysentery: role of oral rehydration therapy [letter]. Lancet 1983;1:654
98. Molla AM, Rahman M, Sarker SA, Sack DA, Molla A. Stool electrolyte content and purging rates in diarrhea caused by rotavirus, enterotoxigenic E. coli and V. cholerae in children. J Pediatr 1981; 98:835-8
99. Bennish ML, Kabir I, Khan A, Azad A, Robertson G. Hyponatremia in shigellosis: incidence and mechanisms [abstract no. 38]. In: Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1988
100. Black RE, Brown KH, Becker S. Effects of diarrhea associated with specific enteropathogens on the growth of children in rural Bangladesh. Pediatrics 1984;73:799-805
101. Jones RN. Antimicrobial activity, spectrum and pharmacokinetics of old and new orally administered cephems. Antimicrobic Newsletter 1988;5:1-7
102. Ginsburg CM, McCracken GH Jr., Petruska M, Olson K. Pharmaco kinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother 1985;28:504-7
103. Neu HC, Chin N-X, Labthavikul P. Comparative in vitro activity and β-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob Agents Chemother 1984;26:174-80
104. Kamimura T, Kojo H, Matsumoto Y, Mine Y, Goto S, Kuwahara S. In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic. Antimicrob Agents Chemother 1984; 25:98-104
105. Neu HC, Chin N-X, Labthavikul P. In vitro activity and β-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074). Antimicrob Agents Chemother 1986; 30:423-8
106. Leitner F, Pursiano TA, Buck RE, Tsai YH, Chisholm DR, Misiek M, Desiderio JV, Kessler RE. BMY 28100, a new oral cephalosporin. Antimicrob Agents Chemother 1987;31:238-43
107. Nelson JD, Haltalin KC. Comparative efficacy of cephalexin and ampicillin for shigellosis and other types of acute diarrhea in infants and children. Antimicrob Agents Chemother 1975;7:415-20
108. Ronsmans C, Bennish ML, Wierzba T. Diagnosis and management of dysentery by community health workers. Lancet 1988;2:552-5
109. Chen LC. Control of diarrheal disease morbidity and mortality: some strategic issues. Am J Clin Nutr 1976;31:2284-91